NFKB1 and prostate carcinoma: In prostate cancer cell lines, EGR1 inhibition decreased cell growth, induced apoptosis [35], and decreased expression of the pro-inflammatory chemokine interleukin 8 (IL8) in a NF-κB-dependent pathway [36].